News & Updates

Slow walk pace, weight gain up CKD risk in adults with obesity

03 Dec 2023

Weight gain and a slow walking pace both influence the risk of chronic kidney disease among adults with obesity who do not have diabetes at baseline, results of a study have shown.

Slow walk pace, weight gain up CKD risk in adults with obesity

03 Dec 2023

Fat mass, fat-free mass linked to mortality in Asians

02 Dec 2023

Asians with extremely high or low fat mass index (FMI) and fat-free mass index (FFMI) are at increased risk of mortality, suggests a study. However, the associations of FMI and FFMI with the mortality risk differ across subgroups and causes of death.

Fat mass, fat-free mass linked to mortality in Asians

02 Dec 2023

SG data affirm link between elevated BP and CVD mortality among individuals with T2D

01 Dec 2023 by

Individuals with type 2 diabetes (T2D) who have high blood pressure (BP) levels are at increased risk of death from cardiovascular disease (CVD), according to a large registry cohort in Singapore. However, the risk increase is also present for those who have low diastolic BP.

SG data affirm link between elevated BP and CVD mortality among individuals with T2D

01 Dec 2023

Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncontrolled on multiple glucose-lowering drugs and reluctant to initiate insulin

30 Nov 2023

Data has demonstrated the efficiency of utilizing a combination of empagliflozin and linagliptin to effectively manage glycemic levels in patients with Type 2 diabetes (T2D) who are uncontrolled on metformin. In this retrospective analysis, we examine the combination of empagliflozin and linagliptin added to existing combination of multiple glucose-lowering medications sans insulin, which revealed significant improvements in both glycemic and cardio-renal outcomes for adults with T2D. This combination therapy was well-tolerated and showed promising clinical effectiveness when used in combination with commonly prescribed antidiabetic drugs for patients with inadequately controlled diabetes.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.

Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncontrolled on multiple glucose-lowering drugs and reluctant to initiate insulin

30 Nov 2023

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023 by

In a substudy of a phase II obesity trial, individuals with MASLD* and obesity benefited significantly from retatrutide, a once-weekly, injectable, novel synthetic molecule that has shown potent agonist action at GIP**, GLP-1***, and glucagon receptors.

Novel tri-agonist confers significant gains for MASLD patients

24 Nov 2023

Zoledronate improves BMD of children with cerebral palsy

23 Nov 2023

Twelve-month treatment with zoledronate significantly increases bone mineral density (BMD) Z-scores without affecting growth in nonambulant children with cerebral palsy (CP), reports a study. However, side effects of the first dose are common.

Zoledronate improves BMD of children with cerebral palsy

23 Nov 2023

Remnant cholesterol predicts NAFLD development

23 Nov 2023

Serum levels of remnant cholesterol may be used to assess an individual’s susceptibility to developing nonalcoholic fatty liver disease (NAFLD), independent of traditional lipid profiles, suggests a recent study.

Remnant cholesterol predicts NAFLD development

23 Nov 2023

Meal replacement-based diet beneficial to T2D patients

22 Nov 2023

A dietary pattern based on meal replacement (MR), compared with conventional diabetic diets (CDs), brings about improvements in glycaemic control and adipose indicators in patients with type 2 diabetes (T2D), according to a study.

Meal replacement-based diet beneficial to T2D patients

22 Nov 2023

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023 by

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

19 Nov 2023

People with high or medium genetic risk of abdominal obesity but who have a healthy lifestyle are less likely to develop coronary heart disease (CHD) than those with low genetic risk and an unhealthy lifestyle, a study has shown.

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

19 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Slow walk pace, weight gain up CKD risk in adults with obesity

Slow walk pace, weight gain up CKD risk in adults with obesity

Fat mass, fat-free mass linked to mortality in Asians

Fat mass, fat-free mass linked to mortality in Asians

SG data affirm link between elevated BP and CVD mortality among individuals with T2D

SG data affirm link between elevated BP and CVD mortality among individuals with T2D

Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncontrolled on multiple glucose-lowering drugs and reluctant to initiate insulin

Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncontrolled on multiple glucose-lowering drugs and reluctant to initiate insulin

Novel tri-agonist confers significant gains for MASLD patients

Novel tri-agonist confers significant gains for MASLD patients

Zoledronate improves BMD of children with cerebral palsy

Zoledronate improves BMD of children with cerebral palsy

Remnant cholesterol predicts NAFLD development

Remnant cholesterol predicts NAFLD development

Meal replacement-based diet beneficial to T2D patients

Meal replacement-based diet beneficial to T2D patients

Dapagliflozin offers cardioprotection in HF patients with T2D

Dapagliflozin offers cardioprotection in HF patients with T2D

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity

Healthy lifestyle helps prevent CHD despite genetic susceptibility to obesity